The United Kingdom and the United States have secured a important trade agreement that will preserve zero levies on UK drug products entering the American market.
Key Provisions of the Deal
As part of the deal, the UK has agreed to boost spending on medicines through the public health system. This move secures that duties on these key exports will remain at nothing for a timeframe of the next three years.
This deal is in response to earlier warnings to hike duties on patented drug products, with potential rates floated as high as double the cost.
"This deal with the UK strengthens the global environment for cutting-edge drugs and establishes long-overdue fairness to U.S.–U.K. drug exports," an announcement noted.
Economic Importance
Drugs constitute one of the Britain's largest exports to the United States, which is by far the primary buyer for major companies like GSK and AstraZeneca.
Trade data show that in the year prior to September, the UK shipped medicines valued at billions to the US. This figure made up a significant portion of British export trade in that timeframe.
"This agreement safeguards work, increases investment and facilitates the UK to establish itself as a worldwide center for biotech and pharma," a government official stated.
Specific UK Commitments
The deal involves several key pledges from the United Kingdom:
- Revised Affordability Limit: The UK will raise the price threshold at which it judges new medicines to be prohibitively costly by a quarter.
- Increased NHS Spending: There is a goal to increase overall public funding on drugs from 0.3 percent of Gross Domestic Product to 0.6 percent over the following ten-year period.
- Payback Limit: The sum pharmaceutical firms must pay back to the NHS to stay within budget will be capped at 15%. Last year, rebates exceeded 20%.
Broader Context
This agreement takes place against a long-running tension between the sector and the UK government over drug pricing and NHS adoption.
These tensions were heightened by arguments that US patients were paying several times more for the identical medicines than people in the Britain and the EU.
Recently, several large drug company projects in the UK have been paused or cancelled, while major investments have been pledged toward projects in the United States.
The Science Minister stated that the NHS must spend more on drugs, noting that its expenditure on drugs had decreased as a percentage of its overall budget over the past decade.
